Literature DB >> 12928650

Depopulated vena caval homograft: a new venous conduit.

Winfield Wells1, Mahmoud Malas, Craig J Baker, Susanne M Quardt, Mark L Barr.   

Abstract

OBJECTIVE: Completion of the Fontan procedure is frequently performed by using an extracardiac conduit between the inferior vena cava and the pulmonary artery. Most centers use a polytetrafluoroethylene graft for the extracardiac conduit, and because re-endothelialization is unlikely, anticoagulation is used for a variable period. This study explores the use of an alternate large-caliber venous conduit.
METHODS: The superior vena cava was replaced in 8 minipigs with either a polytetrafluoroethylene interposition graft (2 pigs) or a depopulated (acellular), cryopreserved superior vena caval homograft (6 pigs). After 6 months, the animals were killed, and the grafts were examined for patency and histology, including immunostaining. No anticoagulation was used.
RESULTS: Polytetrafluoroethylene grafts have a cross-sectional luminal narrowing, ranging from 16% to 40%. Histology showed only partial intimal ingrowth, with excessive subendothelial fibrosis and early calcification. In contrast, the depopulated venous homografts showed minimal luminal narrowing, ranging from 2% to 9%. These grafts were completely repopulated by the recipient with an endothelial lining, which stained positively for factor VIII, and a subendothelial region appropriately recellularized by myofibroblasts, which stained positively for smooth muscle actin and procollagen. There was no evidence of an immune response to the venous homografts, as judged by staining for T-cell surface antigen, CD4, and CD8. Thrombus was not seen in any of the grafts.
CONCLUSION: Depopulated, cryopreserved vena caval homografts might be superior conduits for cavopulmonary connection during completion of the Fontan operation by using the extracardiac conduit technique.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928650     DOI: 10.1016/s0022-5223(03)00208-3

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

Review 1.  Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again.

Authors:  Joseph T Patterson; Thomas Gilliland; Mark W Maxfield; Spencer Church; Yuji Naito; Toshiharu Shinoka; Christopher K Breuer
Journal:  Regen Med       Date:  2012-05       Impact factor: 3.806

2.  Novel utilization of serum in tissue decellularization.

Authors:  Liqiong Gui; Stephen A Chan; Christopher K Breuer; Laura E Niklason
Journal:  Tissue Eng Part C Methods       Date:  2010-04       Impact factor: 3.056

3.  Development of decellularized human umbilical arteries as small-diameter vascular grafts.

Authors:  Liqiong Gui; Akihito Muto; Stephen A Chan; Christopher K Breuer; Laura E Niklason
Journal:  Tissue Eng Part A       Date:  2009-09       Impact factor: 3.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.